- Oral presentation highlighted Iomab-B improves overall
survival in patients with TP53 mutation with active, relapsed or
refractory AML
- Eighth oral presentation of the Phase 3 SIERRA results at ASH
continues to build broad exposure for Iomab-B across key
medical and scientific communities globally
NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today highlighted four presentations at the 65th Annual
American Society of Hematology Annual Meeting & Exposition
(ASH) detailing results from the Phase 3 SIERRA trial of Iomab-B
and Phase 1 trial of Actimab-A in combination with Venetoclax in
patients with relapsed or refractory acute myeloid leukemia (r/r
AML). Iomab-B and Actimab-A are the only two clinical stage
targeted radiotherapies in development for patients with AML, which
is known to be highly sensitive to radiation.
Sandesh Seth, Actinium's Chairman
and CEO, said, "Earlier in 2023 we presented data from both Iomab-B
and Actimab-A highlighting positive outcomes in patients with
relapsed or refractory AML. We are particularly excited by these
results as our trials enrolled patients with difficult to treat
disease as they were heavily pre-treated, elderly in age, or had
adverse cytogenetic or molecular mutations. As evidenced by the
data presented at ASH in the oral presentation of the Phase 3
SIERRA trial results, Iomab-B produced improved outcomes in
patients with a TP53 mutation, which is associated with dismal
outcomes. We are proud to have showcased Iomab-B and Actimab-A at
ASH and excited by the enthusiasm for which the data were received.
We look forward to progressing both programs with key BLA and MAA
filings for Iomab-B next year and advanced development for
Actimab-A."
ASH Presentations and Highlights:
131I-Apamistamab-Led Allogeneic
Hematopoietic Cell Transplant Significantly Improves Overall
Survival in Patients with TP53 Mutated R/R AML
- Patients receiving Iomab-B had significantly greater
median overall survival of 5.49 months compared to 1.66 months in
patients on the control arm that received conventional care
- 24% of patients (37/153) enrolled on the SIERRA trial had a
TP53 mutation, which is associated with the worst outcomes
- Iomab-B produced response rates and overall survival in these
very high-risk patients similar to those observed in patients
without a TP53 mutation
131I-Apamistamab Effectively Achieved
Durable Responses in Patients with R/R AML Irrespective of the
Presence of Multiple High-Risk Factors
- Patients receiving Iomab-B were able to receive a BMT and
achieve durable Complete Remission (dCR), the primary endpoint in
the SIERRA trial, irrespective of having multiple high-risk
factors
- Iomab-B met the dCR rate primary endpoint with high statistical
significance (p<0.0001) with 22% dCR rate in the Iomab-B
arm vs. 0% dCR rate in the control arm
- 53% of patients had 2-3 high-risk factors and 29% had 4-5
high-risk factors that included adverse-risk cytogenetics, age
>65, prior treatment failure with Venetoclax, BMT comorbidity
index > 3, and Karnofsky Performance Status < 90
- There was no statistical difference in the rate of dCR in
patients receiving Iomab-B across the high risk-factor categories
(0-1, 2-3 & 4-5)
High-Dose Targeted Radiation with 131I-Apamistamab
Prior to HCT Demonstrated a Dose-Response for Durable Complete
Remission in Patients with R/R AML
- Patients with higher bone marrow/liver absorbed dose ratios
experienced considerably higher rates of dCR demonstrating a
dose dependent response
- 27% of patients achieving dCR when receiving > 22 Gy to
the liver vs 13.5% dCR rate in patients receiving < 22 Gy to the
liver; maximum tolerable dose in SIERRA was 24 Gy administered to
the liver
- Rates of Grade 3 > treatment emergent events were
similar between patients receiving < 22 Gy to the liver and
those receiving > 22 Gy to the liver
- Iomab-B led BMT produced to significantly higher rates of dCR
with patients achieving dCR having a 92% 1-year overall survival
and 60% 2-year overall survival
- These results demonstrate the importance of maximizing the dose
to target tissues within the established dose tolerances
Updated Results from Phase 1 Study of Targeted Radiotherapy
with Lintuzumab-Ac225 in Combination with Venetoclax in
Relapsed/Refractory AML
- Actimab-A dosed up to 2.0 μCi/kg with Venetoclax in patients
with relapsed/refractory AML was well-tolerated, with a manageable
adverse event profile
- Maximum tolerated dose was not reached with no
dose-limiting toxicities observed at the 3 highest dose levels
(1.0, 1.5 & 2.0 μCi/kg)
- Complete responses were achieved including a complete response
in a patients with prior Venetoclax treatment and a TP53
mutation
- These results support the continued evaluation
of Actimab-A in combination with Venetoclax-based
treatment
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully
improve survival for people who have failed existing oncology
therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an
induction and conditioning agent prior to bone marrow transplant,
and Actimab-A (National Cancer Institute CRADA pivotal development
path), a therapeutic, have demonstrated potential to extend
survival outcomes for people with relapsed and refractory acute
myeloid leukemia. Actinium plans to advance Iomab-B for other blood
cancers and next generation conditioning candidate Iomab-ACT to
improve cell and gene therapy outcomes. Actinium's technology
platform is the basis for collaborations with Astellas Pharma for
solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid
tumors, and several internal programs in solid tumors. Actinium
holds more than 220 patents and patent applications.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
Sources: Granowicz EM, Jonas BA.
Targeting TP53-Mutated Acute Myeloid Leukemia: Research
and Clinical Developments. Onco Targets Ther. 2022 Apr
21;15:423-436. doi: 10.2147/OTT.S265637. PMID: 35479302; PMCID:
PMC9037178.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actiniums-four-presentations-at-ash-highlight-the-positive-outcomes-for-iomab-b-and-actimab-a-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-302011000.html
SOURCE Actinium Pharmaceuticals, Inc.